In 2019, Yokoi et al. analyzed clinical data from 900 EC patients and showed that tumor-derived G-CSF and G-CSF-mediated IL-6 production from the tumor microenvironment are involved in the development of leukocytosis and thrombocytosis. The gene discussed is CSF3; the disease is thrombocytosis disease.